Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeremy Hobart

Showing results (41-50 of 65) with videos related to

Pageof 7
Sort By:
Digital Health|October 23, 2023
An observational study to assess validity and reliability of smartphone sensor-based gait and balance assessments in multiple sclerosis: Floodlight GaitLab protocolMike D Rinderknecht, Mattia Zanon, Tjitske A Boonstra, et al.
Multiple Sclerosis and Related Disorders|April 17, 2026
Analytical and cross-sectional clinical validity of a smartphone-based U-Turn Test in multiple sclerosisMarta Płonka, Rafał Klimas, Dimitar Stanev, et al.
BMJ Open|November 26, 2021
OPTIMISE: MS study protocol: a pragmatic, prospective observational study to address the need for, and challenges with, real world pharmacovigilance in multiple sclerosisRuth Dobson, Matthew Craner, Ed Waddingham, et al.
Brain : a Journal of Neurology|February 4, 2026
Optimal strategies for treatment discontinuation in MOG antibody-associated diseaseWei Z Yeh, Anna Francis, Sarah Cooper, et al.
Multiple Sclerosis and Related Disorders|March 29, 2024
A study of referral bias in NMOSD and MOGAD cohortsMiguel Leal Rato, Bo Chen, Anna Francis, et al.
CNS Drugs|July 26, 2020
Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension StudyTjalf Ziemssen, Ann D Bass, Regina Berkovich, et al.
Neurology and Therapy|July 16, 2020
State of the Art and Future Challenges in Multiple Sclerosis Research and Medical Management: An Insight into the 5th International Porto Congress of Multiple SclerosisMaría José Sá, Ricardo Soares Dos Reis, Ayse Altintas, et al.
Therapeutic Advances in Neurological Disorders|May 25, 2026
Adherence to risk minimization measures for alemtuzumab use in multiple sclerosis: a drug utilization study in four European countriesCarmen de Keijzer, Jian-Yu E, Qian Yang, et al.
Lancet (London, England)|May 28, 2026
Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b studyGavin Giovannoni, Laura Airas, Riley Bove, et al.
JAMA Network Open|January 10, 2022
Factors Associated With Relapse and Treatment of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease in the United KingdomChanjira Satukijchai, Romina Mariano, Silvia Messina, et al.
Pageof 7

Showing results (41-50 of 65) with videos related to

Sort By:
Pageof 7
Digital Health|October 23, 2023
An observational study to assess validity and reliability of smartphone sensor-based gait and balance assessments in multiple sclerosis: Floodlight GaitLab protocolMike D Rinderknecht, Mattia Zanon, Tjitske A Boonstra, et al.
Multiple Sclerosis and Related Disorders|April 17, 2026
Analytical and cross-sectional clinical validity of a smartphone-based U-Turn Test in multiple sclerosisMarta Płonka, Rafał Klimas, Dimitar Stanev, et al.
BMJ Open|November 26, 2021
OPTIMISE: MS study protocol: a pragmatic, prospective observational study to address the need for, and challenges with, real world pharmacovigilance in multiple sclerosisRuth Dobson, Matthew Craner, Ed Waddingham, et al.
Brain : a Journal of Neurology|February 4, 2026
Optimal strategies for treatment discontinuation in MOG antibody-associated diseaseWei Z Yeh, Anna Francis, Sarah Cooper, et al.
Multiple Sclerosis and Related Disorders|March 29, 2024
A study of referral bias in NMOSD and MOGAD cohortsMiguel Leal Rato, Bo Chen, Anna Francis, et al.
CNS Drugs|July 26, 2020
Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension StudyTjalf Ziemssen, Ann D Bass, Regina Berkovich, et al.
Neurology and Therapy|July 16, 2020
State of the Art and Future Challenges in Multiple Sclerosis Research and Medical Management: An Insight into the 5th International Porto Congress of Multiple SclerosisMaría José Sá, Ricardo Soares Dos Reis, Ayse Altintas, et al.
Therapeutic Advances in Neurological Disorders|May 25, 2026
Adherence to risk minimization measures for alemtuzumab use in multiple sclerosis: a drug utilization study in four European countriesCarmen de Keijzer, Jian-Yu E, Qian Yang, et al.
Lancet (London, England)|May 28, 2026
Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b studyGavin Giovannoni, Laura Airas, Riley Bove, et al.
JAMA Network Open|January 10, 2022
Factors Associated With Relapse and Treatment of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease in the United KingdomChanjira Satukijchai, Romina Mariano, Silvia Messina, et al.
Pageof 7